Novo Nordisk A/S
Pagina dedicata companiei Novo Nordisk A/S listata cu simbolul US.NVO
Descriere companie[edit | ]
Novo Nordisk A/S (https://www.novonordisk.com/) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Grafic actiuni companie[edit | ]
Ultimele stiri despre Novo Nordisk A/S (US.NVO)[edit | ]
- Castigul sistemului bancar la nivel record - 03 martie 2026
- Recesiunea tehnica impune prudenta in 2026 - 24 februarie 2026
- Deficitul comercial se reduce usor - 10 februarie 2026
- Romania, cel mai mare importator de seminte de floarea-soarelui - 05 februarie 2026
- Romania, printre cele mai ieftine din UE - 19 ianuarie 2026
- Pilonul 2, randament record in 2025 - 14 ianuarie 2026
- Radiografia companiilor din Romania in 2024 - 25 noiembrie 2025
- Industria pensiilor private din Romania - 06 noiembrie 2025
- Turbinele eoliene la turatie maxima - 06 octombrie 2025
- Constructiile isi continua cresterea - 19 septembrie 2025